US residents can face serious financial barriers to obtaining prescription medications, including disease-modifying medications for multiple sclerosis (MS). We conducted 30-min telephone surveys with 983 persons with MS nationwide, 21—64 years old, to explore how financial and health insurance concerns affect access to services including MS drugs. Almost everyone (96.3%) had some health insurance. Multivariable logistic regression analyses accounted for demographic, disease and insurance characteristics. Only 10.8% of those <40 years old had never received disease-modifying medications, compared with 41.1% of persons aged 60—64. Among the uninsured, 36.8% reported having never taken these medications, compared with 21.2% of persons with health insurance. Adjusted odds ratio (95% CI) of using these drugs in prior 12 months among the uninsured (compared with insured persons) was 0.28 (0.08, 0.95). Just over 16% of persons with public health plans reported that their insurer initially denied coverage for MS medication. When asked about MS medications in general, 22.3% reported having not filled prescriptions, skipping doses or splitting pills because of cost concerns; 22.4% worried `a lot' about getting MS medications when they needed them. Substantial fractions of persons with MS confront financial and health plan-related barriers to obtaining MS drugs. Multiple Sclerosis 2008; 14: 112—122. http://msj.sagepub.com
Wallack SS, Weinberg DB, Thomas CPHealth plans' strategies to control prescription drug spending. Health Aff2004; 23: 141—8.
2.
National Multiple Sclerosis Society.Comparing the disease-modifying drugs. New York: National Multiple Sclerosis Society, 2006. Retrieved from www.nationalmssociety.org/Brochures-Comparing.asp, accessed 16 June 2006.
3.
Calder K.Finding lower-priced prescription drugs. New York: National Multiple Sclerosis Society. Retrieved from www.nationalmssociety.org/healthinsurance_resources.asp, accessed 16 June 2006.
4.
Iezzoni LI, Ngo L.Health, disability, and life insurance experiences of working-age persons with multiple sclerosis. Mult Scler2007; 13: 534—46.
5.
Minden SL, Frankel D., Hadden L., Perloff J., Srinath KP, Hoaglin DCThe Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler2006; 12: 1—15.
6.
Minden SL, Frankel D., Hadden LS, Srinath KP, Perloff JNDisability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. NeuroRehabilitation2004; 19: 55—67.
7.
Whetten-Goldstein K., Sloan FA, Goldstein LB, Kulas EDA comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler1998; 4: 419—25.
8.
RoperStarch Worldwide, Inc. An analysis of non-members. Report prepared for theNational Multiple Sclerosis Society. New York: Roper Starch Worldwide, Inc., 1998.
9.
Adams PF, Marano MACurrent estimates from the National Health Interview Survey, 1994. National Center for Health Statistics. Vital Health Stat1995; 10(193): 1—260.
10.
Iezzoni LI, McCarthy EP, Davis RB, Siebens H.Access to health care and insurance for working-age adults reporting mobility difficulties. Res Soc SciDisability2003; 3: 131—55.
11.
Cohen J.Design and methods of the Medical Expenditure Panel Survey Household Component. AHCPR Pub. No. 97-97-0026. Rockville, MD: Agency for Health Care Policy and Research, 1997.
12.
Harris Interactive, Inc.2000National Organization on Disability/Harris Survey of Americans with Disabilities. Conducted for the National Organization on Disability. New York: Harris Interactive, Inc., 2000.
13.
Hanson K., Neuman P., Voris M.Understanding the Health-Care Needs and Experiences of People with Disabilities. Findings from a 2003 Survey. Menlo Park, CA: The Henry J. Kaiser Family Foundation, 2003.
14.
Hanson KW, Neuman P., Dutwin D., Kasper JDUnderstanding the challenges facing people with disabilities: the role of health insurance. Health Aff Web Exclusive2003 (19 November); W3-552.
15.
Hsu J., Price M., Huang J., Brand R., Fung V., Hui R. et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med2006; 354: 2349—59.
16.
Mohr DC, Goodkin DE, Likosky W., Gatto N., Neilley LK, Griffin C. et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b; relationship to adherence to treatment . Mult Scler1996; 2: 222—6.
17.
Tremlett HL , Oger J.Interrupted therapy: stopping and switching of b-interferons prescribed for MS. Neurology2003; 61: 551—4.
18.
Rio J., Porcel J., Tellez N., Sanchez-Betancourt A., Tintore M., Arevalo MJ et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler2005; 11: 306—9.
19.
The CHAMPIONS Study Group.IM Interferon Beta 1a delays definite multiple sclerosis 5-years after a first demyelinating event. Neurology2006; 66: 678—84.
20.
AvronJ.Part “D” for “defective” — Medicare drug-benefit chaos. N Engl J Med2006; 354: 1339—41.
21.
Slaughter LMMedicare Part D — the product of a broken process. N Engl J Med2006; 354: 2314—15.
22.
Crowley JS, Williams B.Navigating the Medicare Part D prescription drug coverage program. A guide for people with disabilities, benefits counselors, disability organizations and others on ensuring adequate and appropriate access to prescription drugs . Washington, DC: United Cerebral Palsy, 2006. Retrieved from www.ucp.org .
23.
Stuart B., Briesacher BA, Shea DG, Cooper B., Baysac FS, Limcangco MRRiding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff2005; 24(4): 1022—31.
24.
Stuart B., Simoni-Wastila L., Chauncey D.Assessing the impact of coverage gaps in the Medicare Part D drug benefit . Health Aff Web Exclusive2005 (19 April): W5-167—W5-179.
25.
National Multiple Sclerosis Society.Medicare Rx Coverage. What are your options & costs? Retrieved from www.nationalmssociety.org/medicare_options.asp, accessed 15 June 2006.
26.
Anderson GF , Shea DG, Hussey PSDoughnut holes and price controls. Health Aff Web Exclusive2004 (21 July). Retrieved from content.healthaffairs.org.
27.
The Henry J. Kaiser Family Foundation.Voices of beneficiaries: early experiences with the Medicare drug benefit . Menlo Park, CA: The Henry J. Kaiser Family Foundation, Report #7504, April 2006. Retrieved from www.kff.org.
28.
Confavreux C., Paty DWCurrent status of computerization of multiple sclerosis clinical date for research in Europe and North America: the EDMUS/MS-COSTAR connection. Neurology1995; 45: 573—6.
29.
Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B., Coyle PK, Goodman A. et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler1999; 5: 369—76.
30.
Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH et al. Change in MS-related disability in a population-based cohort. A 10-year follow-up study. Neurology2004; 62: 51—9.
31.
Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M.Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985—2000. Neurology2003; 61: 1373—77.
32.
Anderson DW , Ellenberg JH, Leventhaol CM, Reingold SC, Rodriguez M., Silberberg DHRevised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol1992; 31: 333—6.
33.
Krieger N., Chen JT, Waterman PD, Rehkopf DH, Subramanian SVPainting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health2005; 95(2): 312—23.
34.
Geronimus AT , Bound J.Use of census-based aggregate variables to proxy for socioeconomic group: evidence from national samples. Am J Epidemiol1998; 148(5): 475—86.
35.
Krieger N., Chen JT, Waterman PD, Rehkopf DH, Subramanian SVRace/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures—the public health disparities geocoding project. Am J Public Health2003; 93(10): 1655—71.
36.
Braveman PA , Cubbin C., Egerter S., Chideya S., Marchi KS, Metzler M. et al. Socioeconomic status in health research: one size does not fit all. JAMA2005; 294(22): 2879—88.
37.
Clingerman E., Stuifbergen A., Becker H.The influence of resources on perceived functional limitations among women with multiple sclerosis. J Neurosci Nurs2004; 36: 312—321.
38.
Kraft GHImproving health care delivery for persons with multiple sclerosis. Phys Med Rehabil Clin N Am1998; 9: 703—15.
39.
McLaughlin CMCommunity programs and resources for persons with multiple sclerosis. Phys Med Rehabil Clin N Am1998; 9: 689—702.
